Floatz logo

APOMORPHINUM

Idiopathic Generalized Epilepsy

Institut National de la Santé Et de la Recherche Médicale, FranceSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Idiopathic Generalized Epilepsy cohort.

Asset / SponsorPhaseRating
Valproic Acid
Mazandaran University of Medical Sciences
Phase 4BB
Cenobamate
SK Life Science, Inc.
Phase 3BB
Valproic Acid
Mazandaran University of Medical Sciences
D
Fycompa
Eisai Limited
D

Same molecule, other indications

APOMORPHINUM is also rated in:

Parkinson diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
movement disorderDormant
BB
Indicative ·
66 / 100
View asset →
AkinesiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →